A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Phase 2
37
about 6.4 years
1–39
2 sites in MA
What this study is about
This trial is testing whether it's possible to give decitabine and filgrastim after a stem cell transplant in children and young adults with certain blood cancers. The treatment aims to prevent the cancer from returning after the transplant.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Decitabine
- 2.Take Filgrastim
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
decitabine, filgrastim
injection, intravenous, injection (Injection)
Secondary: 24-Month Probability Event-Free Survival (EFS), 24-Month Probability Overall Survival (OS), Treatment Tolerability Rate (TTR)
Oncology, Musculoskeletal